Evotec and Forge Therapeutics form strategic “superbug” alliance
Evotec AG today announced a strategic alliance with Forge Therapeutics, Inc. (“Forge”) to advance its novel Gram-negative antibiotic programme targeting ‘LpxC’ for the treatment of bacterial infections including those caused by drug resistant ‘superbugs’. L
LpxC has been recognised as an attractive antibacterial target for more than the past 15 years; however, a lack of suitable chemical starting points has hampered its progress. Forge has been applying its proprietary metal-binding pharmacophores (“MBP”) library and processes and has been able to identify potent drugable inhibitors of LpxC.
29 June 2018
Brokerage Event for 2019 SC1 calls (Oslo)
21 June 2018
Bone Innovation Summit (Lübeck)